Status:
TERMINATED
ActaVisc and ActaVisc Mx Intra-articular Injection for Pain Associated With Osteoarthritis in the Knee
Lead Sponsor:
Carbylan Therapeutics, Inc.
Conditions:
Osteoarthritis
Eligibility:
All Genders
40-85 years
Phase:
NA
Brief Summary
To evaluate the safety and performance of ActaVisc™ intra-articular injection (ActaVisc) and ActaVisc Mx, for management of pain associated with osteoarthritis in the knee in patients who have failed ...
Eligibility Criteria
Inclusion
- Osteoarthritis (OA) grade 2 or 3.
- Symptoms in the treatment knee for at least 12 months.
- Fully ambulatory patient.
Exclusion
- Secondary OA resulting from rheumatoid arthritis, chondrocalcinosis, osteonecrosis, chronic fibromyalgia or other autoimmune disease.
- Generalized symptomatic OA in lower extremity joints other than the knees, inflammatory joint disease, bursitis, OA in the hips, or other condition that may interfere with study assessments.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT00665574
Start Date
March 1 2008
End Date
June 1 2009
Last Update
July 14 2009
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Daugavpils Pilsetas Centrala Slimnica
Daugavpils, Latvia
2
State Hospital of Traumatology and Orthopaedics
Riga, Latvia